Stockreport

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF The reported figure is also wider than the year-ago quarter's loss of 45 cents per share. Currently, Immunovant does not have any approved product in its portfolio. As [Read more]